The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma

Citation
Dtt. Chua et al., The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma, CANCER, 92(11), 2001, pp. 2845-2855
Citations number
17
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER
ISSN journal
0008543X → ACNP
Volume
92
Issue
11
Year of publication
2001
Pages
2845 - 2855
Database
ISI
SICI code
0008-543X(200112)92:11<2845:TPVOT1>2.0.ZU;2-X
Abstract
BACKGROUND. A retrospective analysis of treatment outcomes in patients with nasopharyngeal carcinoma (NPC) was performed in which the newly revised 19 97 American Joint Committee on Cancer (AJCC) stage classification was appli ed and compared with the 1988 AJCC and Ho stage classifications, with empha sis on the predictive value of different staging systems in determining fai lure patterns in NPC. METHODS. Three hundred and twenty-four patients with newly diagnosed NPC tr eated between September 1989 and August 1991 and originally staged accordin g to Ho stage classification were re-staged according to the 1988 and 1997 AJCC stage classifications. In addition to stage grouping, patients were al so classified into the following prognostic categories to study the failure patterns: early disease group (T1-2N0-1), advanced local disease group (T3 -4N0-1), advanced nodal disease group (T1-2N2-3), and advanced locoregional disease group (T3-4N2-3). The overall survival (OAS), relapse-free surviva l (RFS), local relapse-free survival, nodal relapse-free survival, and dist ant metastases-free survival were compared among different stage groups and prognostic categories in the three staging systems. RESULTS. In the new AJCC system, the percentages of patients with Stage I, II, III, and IV disease were 15.1%, 31.5%, 28.1%, and 25.3%, respectively, whereas most patients were classified as having Stage IV disease (65.7%) in the old AJCC system and Stage II or III disease (74.1%) in the Ho system. The 5 year OAS rates in the 1997 AJCC Stage I, II, III, and IV disease were 97.7%, 78.7%, 79.5%, and 61.4%, respectively. The corresponding 5 year RFS rates were 95.7%, 64.7%, 54.5%, and 41.1%. Using the 1997 AJCC system to d efine the four prognostic categories, the early disease group had the lowes t incidence of relapse (27.6%) and death (18.4%), whereas the advanced loco regional disease group had the highest incidence of relapse (61.4%) and dea th (43.2%). Both the advanced local disease group and the advanced nodal di sease group had similar rates of relapse (46.7% vs. 47.2%), but local relap se was the major cause of failure in the former group (61.8%), whereas dist ant metastases was the major cause in the latter group (44%). CONCLUSIONS. Using the 1997 AJCC staging system, the authors observed a bet ter distribution of patient numbers as well as segregation of survival curv es among different stage groups. Moreover, prognostic categories with disti nct prognosis and failure patterns were definable by the new system, which has important implications in selecting appropriate patient treatment strat egies. Cancer 2001;92: 2845-55. (C) 2001 American Cancer Society.